{"id":"combination-of-irinotecan-and-cisplatin","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Irinotecan works by inhibiting topoisomerase I, an enzyme involved in DNA replication, causing DNA damage and triggering cell death. Cisplatin, on the other hand, forms DNA crosslinks, which also lead to cell death. Both mechanisms are particularly effective against rapidly dividing cancer cells.","oneSentence":"Irinotecan inhibits topoisomerase I, while cisplatin induces DNA crosslinks, both mechanisms leading to cell death in rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:43.100Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":320},{"nctId":"NCT03715933","phase":"PHASE1","title":"Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas","status":"RECRUITING","sponsor":"Inhibrx Biosciences, Inc","startDate":"2018-10-08","conditions":"Ewing Sarcoma","enrollment":321},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT07376499","phase":"PHASE2","title":"Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2026-01-25","conditions":"Small Cell Lung Cancer","enrollment":31},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT05945823","phase":"PHASE2","title":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-07-13","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer","enrollment":53},{"nctId":"NCT03533582","phase":"PHASE3","title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-24","conditions":"Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma","enrollment":537},{"nctId":"NCT04329494","phase":"PHASE1","title":"PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-08-21","conditions":"Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8","enrollment":49},{"nctId":"NCT03170960","phase":"PHASE1","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2017-09-05","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":914},{"nctId":"NCT03872947","phase":"PHASE1","title":"A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toray Industries, Inc","startDate":"2019-04-26","conditions":"Solid Tumor, Colorectal Cancer, Cholangiocarcinoma","enrollment":138},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT06951841","phase":"PHASE4","title":"Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2025-04-30","conditions":"Small Cell Lung Cancer","enrollment":31},{"nctId":"NCT06621563","phase":"PHASE1","title":"Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-12-14","conditions":"Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer","enrollment":780},{"nctId":"NCT05535218","phase":"PHASE2","title":"Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Claudia Guerrieri","startDate":"2023-09-20","conditions":"Muscle-invasive Urothelial Carcinoma of the Bladder","enrollment":48},{"nctId":"NCT01648023","phase":"PHASE2","title":"Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin","status":"COMPLETED","sponsor":"Robert C. Martin","startDate":"2012-07","conditions":"Unresectable Intrahepatic Cholangiocarcinoma","enrollment":49},{"nctId":"NCT03535727","phase":"PHASE1, PHASE2","title":"A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-06-21","conditions":"Adenocarcinoma, Pancreatic Neoplasms, Neoplasm, Glandular","enrollment":48},{"nctId":"NCT03904927","phase":"PHASE2","title":"Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Fudan University","startDate":"2019-02-01","conditions":"Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma","enrollment":104},{"nctId":"NCT04931420","phase":"PHASE2","title":"Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2022-05-19","conditions":"Metastatic Cancer, Foregut Carcinoid Tumor, Gastric Adenocarcinoma","enrollment":""},{"nctId":"NCT06485739","phase":"PHASE4","title":"Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2024-07-01","conditions":"Neuroendocrine Tumors","enrollment":20},{"nctId":"NCT03017326","phase":"PHASE3","title":"Paediatric Hepatic International Tumour Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2017-08-24","conditions":"Hepatoblastoma, Carcinoma, Hepatocellular","enrollment":450},{"nctId":"NCT06364046","phase":"NA","title":"Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC","status":"NOT_YET_RECRUITING","sponsor":"The Central Hospital of Lishui City","startDate":"2024-04-01","conditions":"Carcinoma, Small Cell Lung Cancer","enrollment":56},{"nctId":"NCT05248022","phase":"NA","title":"Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2024-02-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":98},{"nctId":"NCT02324543","phase":"PHASE1, PHASE2","title":"Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-02","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":47},{"nctId":"NCT00057837","phase":"PHASE2","title":"Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-07-14","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":140},{"nctId":"NCT00033657","phase":"PHASE2","title":"Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2002-08-15","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":97},{"nctId":"NCT02937116","phase":"PHASE1","title":"First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2016-10-19","conditions":"Cancer, Solid Tumor","enrollment":233},{"nctId":"NCT05235542","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors","status":"UNKNOWN","sponsor":"Akeso","startDate":"2022-07-12","conditions":"Advanced Malignant Tumors","enrollment":130},{"nctId":"NCT05320874","phase":"PHASE1","title":"A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.","status":"NOT_YET_RECRUITING","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2022-04","conditions":"Advanced Solid Tumor","enrollment":232},{"nctId":"NCT00381706","phase":"PHASE2","title":"Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2006-09-15","conditions":"Esophageal Cancer","enrollment":245},{"nctId":"NCT04789941","phase":"PHASE2","title":"How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-04-01","conditions":"Locally Advanced Cervical Carcinoma","enrollment":50},{"nctId":"NCT00023868","phase":"PHASE3","title":"Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)","status":"TERMINATED","sponsor":"American College of Radiology Imaging Network","startDate":"2001-11-01","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":""},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT04453930","phase":"PHASE2","title":"A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-06-08","conditions":"Small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT02157792","phase":"PHASE1","title":"M6620 First in Human Study","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2012-12-10","conditions":"Advanced Solid Tumor","enrollment":200},{"nctId":"NCT03168594","phase":"PHASE2","title":"Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma","status":"TERMINATED","sponsor":"Peking University","startDate":"2017-04-29","conditions":"Neuroendocrine Carcinoma","enrollment":66},{"nctId":"NCT01014767","phase":"PHASE3","title":"Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors","status":"TERMINATED","sponsor":"Tufts Medical Center","startDate":"2009-11","conditions":"Brain Cancer, Choroid Plexus Tumors","enrollment":27},{"nctId":"NCT01040312","phase":"","title":"An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2009-10-15","conditions":"Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer","enrollment":321},{"nctId":"NCT00215501","phase":"PHASE1","title":"Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2001-11","conditions":"Solid Tumor","enrollment":54},{"nctId":"NCT00954512","phase":"PHASE1, PHASE2","title":"Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09-25","conditions":"Neoplasms","enrollment":15},{"nctId":"NCT01608464","phase":"PHASE2","title":"Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer","status":"TERMINATED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2012-05","conditions":"Carcinoma of Esophagus","enrollment":170},{"nctId":"NCT00045162","phase":"PHASE3","title":"S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2002-11","conditions":"Lung Cancer","enrollment":671},{"nctId":"NCT03061058","phase":"PHASE3","title":"Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2013-04-01","conditions":"Stomach Neoplasms, Chemotherapy Effect, Chemotherapeutic Toxicity","enrollment":240},{"nctId":"NCT00808899","phase":"PHASE2","title":"Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2008-12","conditions":"Neuroblastoma","enrollment":4},{"nctId":"NCT00142350","phase":"PHASE3","title":"A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Japan Clinical Oncology Group","startDate":"2000-11","conditions":"Gastric Cancer","enrollment":690},{"nctId":"NCT00012220","phase":"PHASE2","title":"Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2001-01","conditions":"Pancreatic Cancer","enrollment":259},{"nctId":"NCT00354679","phase":"PHASE2","title":"Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-04","conditions":"Esophageal Cancer","enrollment":34},{"nctId":"NCT01977235","phase":"PHASE2","title":"Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Third Military Medical University","startDate":"2013-09","conditions":"Small Cell Lung Carcinoma","enrollment":110},{"nctId":"NCT00590031","phase":"PHASE2","title":"Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2002-11","conditions":"Esophageal Carcinoma","enrollment":61},{"nctId":"NCT00857246","phase":"PHASE2","title":"Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2005-07","conditions":"Gastric Cancer, Stomach Cancer","enrollment":30},{"nctId":"NCT00397904","phase":"PHASE2","title":"Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-10","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":16},{"nctId":"NCT00059761","phase":"PHASE1","title":"Chemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2003-03","conditions":"Lung Cancer","enrollment":36},{"nctId":"NCT01574092","phase":"PHASE2","title":"Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas","status":"COMPLETED","sponsor":"Hospital Sant Joan de Deu","startDate":"2009-11","conditions":"Pediatric High Risk Gliomas","enrollment":39},{"nctId":"NCT00391586","phase":"PHASE2","title":"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung","status":"TERMINATED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2006-07","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":45},{"nctId":"NCT00052494","phase":"PHASE1","title":"Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2003-04","conditions":"Lung Cancer","enrollment":9},{"nctId":"NCT00136955","phase":"PHASE2","title":"Irinotecan Study For Cervical Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-06","conditions":"Uterine Cervical Neoplasms","enrollment":41},{"nctId":"NCT01480986","phase":"PHASE2","title":"IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC","status":"COMPLETED","sponsor":"Peking University","startDate":"2011-09","conditions":"Progression Free Survival of the Treatment","enrollment":40},{"nctId":"NCT02323737","phase":"PHASE2","title":"Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2010-07","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":62},{"nctId":"NCT00165490","phase":"PHASE2","title":"Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2004-08","conditions":"Adenocarcinoma of Esophagus, Squamous Cell Carcinoma of Esophagus","enrollment":19},{"nctId":"NCT00290719","phase":"PHASE1","title":"Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2005-11","conditions":"Esophageal Cancer","enrollment":6},{"nctId":"NCT01379482","phase":"PHASE2","title":"Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2005-01","conditions":"Peritoneal Carcinomatosis, Gastric Cancer","enrollment":18},{"nctId":"NCT01444521","phase":"PHASE2","title":"Genotype-drive Study of Irinotecan-Cisplatin Combination for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2011-04","conditions":"Gastric Cancer","enrollment":50},{"nctId":"NCT00046917","phase":"PHASE1","title":"Combination Chemotherapy in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-07","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":13},{"nctId":"NCT00005791","phase":"PHASE1","title":"Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1999-10","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT00003111","phase":"PHASE2","title":"Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"1997-04","conditions":"Lung Cancer","enrollment":10},{"nctId":"NCT00003742","phase":"PHASE1","title":"Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1998-10","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT00005638","phase":"PHASE1","title":"Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1999-10","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":""},{"nctId":"NCT00006000","phase":"PHASE1","title":"SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2000-08","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT00066391","phase":"PHASE2","title":"Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2003-06","conditions":"Penile Cancer","enrollment":""},{"nctId":"NCT00614965","phase":"PHASE2","title":"Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2006-11","conditions":"Non Small Cell Lung Cancer","enrollment":124},{"nctId":"NCT00004103","phase":"PHASE2","title":"Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"1998-07","conditions":"Gastric Cancer","enrollment":""},{"nctId":"NCT00874328","phase":"PHASE1, PHASE2","title":"A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2008-10","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":74},{"nctId":"NCT00249977","phase":"PHASE1","title":"Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2003-04","conditions":"Solid Tumors, Cancer","enrollment":21},{"nctId":"NCT00045604","phase":"PHASE1","title":"Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2002-07","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT00263016","phase":"PHASE2","title":"Docetaxel in Non Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2005-05","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"combination of irinotecan and cisplatin","genericName":"combination of irinotecan and cisplatin","companyName":"Japan Clinical Oncology Group","companyId":"japan-clinical-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Irinotecan inhibits topoisomerase I, while cisplatin induces DNA crosslinks, both mechanisms leading to cell death in rapidly dividing cancer cells. Used for Metastatic colorectal cancer, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}